GENE ONLINE|News &
Opinion
Blog

2021-07-18| Asia-PacificIPO

Could this Biotech be the First Billion-Dollar Hong Kong Startup to Go Public?

by Tyler Chen
Share To

Hong Kong’s Prenetics might be the first billion-dollar Hong Kong startup to go public. It is reported that Prenetics is planning a merger with a special purpose acquisition company (SPAC) called Artisan Acquisition (Artisan) by the end of 2021, for a value estimated to be over $1.3 billion.

Artisan has already raised $339 million in its initial public offering (IPO) and has obtained $60 million through forward purchase agreements with Aspex and PAG. However, it should be noted that it is not a done deal yet due to several factors that will come into play.

 

SPAC Explained

SPAC is a relatively new way to go public. The SPACs will go through the traditional IPO process to raise money and only use them to acquire or merge with a private firm. By doing so, the acquired company can evade the IPO process and be listed on the board through the SPAC’s shell. As a result, there has been an increasing number of SPAC deals in the biotech industry.

 

Prenetics’ Biggest Strength

Prenetics is well-known in the diagnostic and genetic testing industry, especially during the COVID-19 pandemic. The firm has installed COVID-19 screening devices in Hong Kong International airport and the London Heathrow Airport to accelerate the testing process of travelers.

Other than that, Prenetics in April announced a 3-year collaboration with the Oxford University to further develop Oxford’s rapid molecular testing technology for infectious diseases to deliver fast and accurate molecular testing globally.

Related Article: Oxford, Prenetics Join Forces To Scale Award-Winning Rapid Molecular Testing Technology

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
CK Life Sciences and CK Hutchison Invest in Taiwanese Liquid Biopsy Candidate
2022-07-26
Human Longevity Plans to Merge With Blank Check Company to Go Public
2022-06-22
Quion Licenses Two Rare Skin Disease Candidates to Hong Kong WinHealth
2022-06-16
LATEST
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
Scientists Identify New Genetic Variant Related to Obesity
2022-12-01
Micronbrane Medical Aspires to Further Clinical Collaboration Following the Successful Series A Funding
2022-12-01
FDA Revokes Authorization Of Eli Lilly’s COVID-19 Antibody
2022-12-01
Eisai Unveils Lecanemab Data Following Reports of Second Alzheimer’s Patient Death
2022-11-30
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
2022-11-30
Gland Pharma Dispels Rumors Of Fosun Sale, Acquires Cenexi In Separate Development
2022-11-30
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!